Agilvax: AgilVax Announces Expansion of Series A-1 Financing
AgilVax, Inc., a biopharmaceutical company developing targeted antibody-based products to treat multiple types of cancer in combination with chemotherapy, checkpoint, and KRAS inhibitors, announced that it closed an expansion of its Series A-1 financing with an additional investment of $1.5 million from its existing investors, bringing the total capital raised to nearly $10 million.
Read full article »
Agilvax is a biotechnological company that focuses on the discovery and development of immunotherapies and targeted vaccines.
Read more